
Santen Pharmaceutical Co. Ltd.
SNPHY | OTC
$11.23
+$0.45 (+4.17%)
At close: Oct 30, 2026, 3:15 PM ET
$11.23
$0.00 (0.00%)
After-hours:
Oct 30, 2026, 4:00 PM ET
TTM Period Ending | Q1 2027 Jun 30, 2026 | Q4 2026 Mar 31, 2026 | Q3 2026 Dec 31, 2025 | Q2 2026 Sep 30, 2025 | Q1 2026 Jun 30, 2025 | Q4 2025 Mar 31, 2025 | Q3 2025 Dec 31, 2024 | Q2 2025 Sep 30, 2024 | Q1 2025 Jun 30, 2024 | Q4 2024 Mar 31, 2024 | Q3 2024 Dec 31, 2023 | Q2 2024 Sep 30, 2023 | Q1 2024 Jun 30, 2023 | Q4 2023 Mar 31, 2023 | Q3 2023 Dec 31, 2022 | Q2 2023 Sep 30, 2022 | Q1 2023 Jun 30, 2022 | Q4 2022 Mar 31, 2022 | Q3 2022 Dec 31, 2021 | Q2 2022 Sep 30, 2021 | Q1 2022 Jun 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 291.84B | 291.62B | 287.99B | 291.48B | 293.97B | 300B | 301.91B | 302.56B | 304.35B | 301.97B | 302.08B | 295.93B | 285.89B | 279.04B | 270.24B | 266.41B | 266.8B | 266.26B | 263.62B | 259.46B | 257.03B |
Cost of Revenue | 128.13B | 130.65B | 132.97B | 134.9B | 137.15B | 137.79B | 138.32B | 136.58B | 134.81B | 132.73B | 128.48B | 125.56B | 123.86B | 122.47B | 122.12B | 122.82B | 121.02B | 119.02B | 114.81B | 111.2B | 110.28B |
Gross Profit | 163.72B | 160.97B | 155.02B | 156.58B | 156.82B | 162.22B | 163.58B | 165.98B | 169.54B | 169.24B | 173.61B | 170.37B | 162.03B | 156.57B | 148.12B | 143.59B | 145.78B | 147.23B | 148.81B | 148.26B | 146.75B |
Operating Income | 45.75B | 45.22B | 41.27B | 42.78B | 44.23B | 50.15B | 48.12B | 51.51B | 53.08B | 52.3B | 53.28B | 46.75B | 36.64B | 32.02B | 29.19B | 28.15B | 34.95B | 36.36B | 36.49B | 36.97B | 38.53B |
Interest Income | 1.97B | 1.64B | 3.91B | 3.88B | 3.93B | 4B | 1.69B | 1.75B | 1.6B | 1.95B | 1.85B | 1.79B | 1.77B | 2.1B | 3.27B | 3.38B | 3.34B | 2.54B | 1.54B | 1.45B | 1.41B |
Pretax Income | 48.33B | 47.44B | 40.25B | 41.28B | 41.48B | 47.48B | 31.62B | 29.64B | 30.46B | 29.87B | 39.35B | 37.38B | -2.01B | -5.8B | -1.65B | -1.88B | 35.52B | 36B | 11.14B | 12.47B | 13.24B |
Net Income | 38.68B | 37.36B | 30.61B | 31.42B | 31.5B | 36.26B | 27.5B | 26.13B | 26.86B | 26.64B | 27.73B | 26.37B | -11.2B | -14.95B | -8.2B | -9.13B | 26.54B | 27.26B | 7.7B | 9.96B | 10.62B |
Selling & General & Admin | 91.75B | 89.57B | 88.05B | 88.27B | 87.79B | 87.97B | 91.48B | 90.57B | 91.84B | 91.53B | 95.5B | 97.14B | 97.9B | 96.26B | 89.68B | 87.14B | 83.48B | 84.5B | 87.06B | 85.96B | 84.45B |
Research & Development | 26.23B | 26.19B | 25.7B | 25.53B | 24.81B | 24.1B | 23.98B | 23.9B | 24.62B | 25.42B | 24.82B | 26.49B | 27.5B | 28.3B | 29.26B | 28.31B | 27.36B | 26.38B | 25.26B | 25.33B | 24.62B |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -855M |
Operating Expenses | 117.97B | 115.76B | 113.75B | 113.8B | 112.6B | 112.07B | 115.46B | 114.47B | 116.46B | 116.94B | 120.33B | 123.63B | 125.39B | 124.55B | 118.93B | 115.45B | 110.83B | 110.88B | 112.32B | 111.29B | 108.21B |
Interest Expense | 1.98B | 1.99B | 2.88B | 2.84B | 3.06B | 2.72B | 3B | 3.43B | 3.28B | 3.04B | 2.15B | 2.57B | 2.49B | 2.45B | 2.13B | 1.3B | 1.05B | 1.21B | 1.07B | 1.05B | 1.58B |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 246.1B | 246.41B | 246.73B | 248.7B | 249.74B | 249.86B | 253.79B | 251.05B | 251.27B | 249.67B | 248.8B | 249.18B | 249.26B | 247.02B | 241.05B | 238.27B | 231.85B | 229.9B | 227.13B | 222.49B | 218.5B |
Income Tax Expense | 9.43B | 9.88B | 9.74B | 10.27B | 10.37B | 11.63B | 4.15B | 3.51B | 3.56B | 3.17B | 11.67B | 11.07B | 9.26B | 9.18B | 6.55B | 7.21B | 8.96B | 8.77B | 3.51B | 2.63B | 2.76B |
Shares Outstanding (Basic) | 321.34M | 325.02M | 322.72M | 329.97M | 339.17M | 341.36M | 343.09M | 349.49M | 359.15M | 363.21M | 353.63M | 360.45M | 372.78M | 377.03M | 385.52M | 379.87M | 396.75M | 400.27M | 399.77M | 399.73M | 399.63M |
Shares Outstanding (Diluted) | 322.6M | 325.72M | 323.64M | 330.15M | 340.16M | 341.72M | 344.41M | 350.22M | 360.44M | 363.21M | 354.92M | 361.6M | 373.98M | 377.03M | 386.55M | 379.87M | 397.31M | 400.55M | 400.54M | 400.48M | 400.42M |
EPS (Basic) | 119.09 | 114.03 | 91.91 | 92.83 | 91.69 | 103.97 | 78.32 | 73.71 | 75.02 | 73.34 | 76.22 | 70.98 | -29.18 | -40.33 | -23.63 | -26.52 | 66.46 | 68.15 | 19.26 | 24.94 | 26.61 |
EPS (Diluted) | 118.82 | 113.80 | 91.75 | 92.64 | 91.46 | 103.68 | 78.06 | 73.48 | 74.76 | 73.11 | 75.99 | 70.79 | -29.29 | -40.37 | -23.68 | -26.55 | 66.40 | 68.07 | 19.19 | 24.84 | 26.49 |
EBITDA | 67.88B | 67.79B | 61.33B | 62.21B | 62.28B | 68.15B | 52.73B | 51.35B | 52.59B | 51.09B | 59.22B | 57.11B | 17.3B | 13.9B | 18.14B | 17.19B | 54.28B | 54.26B | 53.47B | 53.94B | 55.74B |
EBIT | 49.3B | 49.44B | 43.13B | 44.11B | 44.54B | 50.2B | 34.62B | 33.07B | 33.74B | 32.91B | 41.5B | 39.95B | 486M | -3.35B | 481M | -580M | 36.57B | 37.21B | 36.18B | 36.69B | 38.91B |
Depreciation & Amortization | 18.58B | 18.36B | 18.2B | 18.09B | 17.74B | 17.95B | 18.11B | 18.29B | 18.85B | 18.18B | 17.72B | 17.16B | 16.81B | 17.25B | 17.66B | 17.77B | 17.71B | 17.06B | 17.29B | 17.25B | 16.83B |
Add to Watchlist
Select watchlists to add or remove SNPHY